Prostate cancer is the second most common cancer affecting men globally, with diagnostic methods and risk assessment remaining a challenge despite decades of research. For years, the prostate-specific ...

Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...

A study of men with a family history of prostate cancer has discovered an inherited form of prostate cancer. The inherited ...

Genomic tests are revolutionizing prostate cancer care, enabling precise, personalized treatment tailored to each patient.

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help doctors make better decisions ...

Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...

A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...

For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs) do not consistently influence risk ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...